期刊文献+

9-[2-(膦酰甲氧基)乙基]腺嘌呤一钠盐在比格犬体内的毒代动力学和毒理学研究(英文) 被引量:1

Toxicokinetics and toxicological studies of sodium 9-[2- (phosphonomethoxy) ethyl] adenine in beagle dogs
下载PDF
导出
摘要 目的为9-[2-(膦酰甲氧基)乙基]腺嘌呤一钠盐(PMEA-Na)重复给药的毒性研究提供毒代动力学资料。方法采用液相色谱质谱联用方法测定样品中的药物浓度,数据经统计矩方法处理得到毒代动力学参数,并完成血清生化学及组织病理学检测。结果比格(Beagle)犬静脉单次及多次给药(14 d,每日1次)后,在给药剂量范围内, AUC均表现为剂量依赖性。在1.0, 3.0与6.0 mg·kg-1PMEA-Na时,AUC分别为(2.3±0.5),(8.4±1.6),(17.5±3.7)mg·L-1·h(单剂量)和(5.0±0.4),(15.9±3.2),(30.3±4.7) mg·L-1·h(多剂量)。PMEA-Na主要经肾脏排出体外,且给药14 d后肾功能受损药物排泄能力降低。与对照组比较, 6.0 mg·kg-1组血清生化学检测指标丙氨酸氨基转换酶、总胆红素、尿素氮、肌酐及甘油三酯均升高,葡萄糖水平下降。6.0 mg·kg-1组的组织病理学检查发现肝脏和肾脏有明显的病理形态学改变。结论比格犬经静脉多次给PMEA-Na 14 d后出现毒性反应,毒性靶器官主要为肾脏和肝脏。 AIM To provide toxicokinetics data for toxicity studies of repeated doses of sodium 9-[ 2- ( phosphonomethoxy ) ethyl ] adenine ( PMEA-Na ). METHODS The concentrations of PMEA-Na in plasma and urine were determined by HPLC/MS/MS method after single and multiple iv administrations in dogs. Data were executed by the statistical moment method to acquire the toxicokinetics parameters. Serum biochemical tests and histopathological examination were performed. RESULTS The system exposure of PMEA- Na in dogs was dose-dependent over the dose range of 1.0 -6.0 mg·kg^-1 The areas under the plasma concentration-time curve of PMEA-Na after single and multiple iv administrations at 1.0, 3.0 and 6.0 mg· kg^-1 dosage were (2.3 ±0.5), (8.4±1.6), (17.5 ± 3.7) and (5.0±0.4), (15.9±3.2), (30.3± 4.7 ) mg· L^- 1· h, respectively. The urinary excretion of PMEA-Na in 72 h after iv administration was ( 87.0 ± 4.8)% at the dose of 3.0mg·kg^-1. In 6.0 mg·kg^-1 dose group, liver enzyme activity of glutamic-pyruvic transaminase and serum levels of total bilirubin, blood urea nitrogen, creatinine and triglycerides were all significantly elevated ; glucose level significantly decreased comparing with the control group. Histopathological observation showed distinct pathological changes in liver and kidney tissues of 6.0 mg · kg^-1 dose group. CONCLUSION There was evidence of toxicity after repeated-dose ( 14 d ) of PMEA-Na in dogs and the major toxicity target organs were the kidney and liver.
出处 《中国药理学与毒理学杂志》 CAS CSCD 北大核心 2006年第6期461-467,共7页 Chinese Journal of Pharmacology and Toxicology
基金 国家高技术研究发展计划(863)资助项目(2004AA2Z3776)~~
关键词 9-[2-(膦酰甲氧基)乙基]腺嘌呤-钠盐 毒代动力学 病理学 sodium 9- [ 2- ( phosphonomethoxy ) ethyl ] adenine toxicokinetics pathology
  • 相关文献

参考文献14

  • 1Ray AS,Vela JE,Olson L,Fridland A.Effective metabolism and long intracellular half life of the anti-hepatitis B agent adefovir in hepatic cells[J].Biochem Pharmacol,2004,68(9):1825-1831.
  • 2Naesens L,Balzarini J,De Clercq E.Pharmacokinetics in mice of the anti-retrovirus agent 9-(2-phosphonylmethoxyethyl) adenine[J].Drug Metab Dispos,1992,20(5):747-752.
  • 3Shaw JP,Louie MS,Krishnamurthy VV,Arimilli MN,Jones RJ,Bidgood AM,et al.Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats[J].Drug Metab Dispos,1997,25(3):362-366.
  • 4Cundy KC,Shaw JP,Lee WA.Oral,subcutaneous,and intramuscular bioavailabilities of the antiviral nucleotide analog 9-(2-phosphonylmethoxyethyl) adenine in cynomolgus monkeys[J].Antimicrob Agents Chemother,1994,38(2):365-368.
  • 5Cundy KC,Barditch-Crovo P,Walker RE,Collier AC,Ebeling D,Toole J,et al.Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients[J].Antimicrob Agents Chemother,1995,39(11):2401-2405.
  • 6Gundert-Remy U,Sonich-Mullin C.The use of toxicokinetic and toxicodynamic data in risk assessment:an international perspective[J].Sci Total Environ,2002,288(1-2):3-11.
  • 7Baldrick P.Toxicokinetics in preclinical evaluation[J].Drug Discov Today,2003,8(3):127-33.
  • 8Zhao YL.Make pathological specimen[A].In:Wang BY,Li YS,Huang GS,Zhang YQ,ed.Pathological Technology(病理实验技术)[M].Beijing:People′s Medical Publishing House,2000.15-30.
  • 9Mesnil F,Dubruc C,Mentre F,Huet S,Mallet A,Thenot JP.Pharmacokinetic analysis of mizolastine in healthy young volunteers after single oral and intravenous doses:noncompartmental approach and compartmental modeling[J].J Pharmacokinet Biopharm,1997,25(2):125-147.
  • 10孟志云,窦桂芳,孙文种,朱晓霞,张亮,汤仲明.阿德福韦二吡呋酯在猕猴体内的药代动力学及在大鼠体内的组织分布[J].中国药理学与毒理学杂志,2003,17(6):447-450. 被引量:4

二级参考文献7

  • 1[1]Bronson JJ, Ho HT, De Boeck H, Woods K, Ghazzouli L, Martin JC, et al. Biochemical pharmacology of acyclic nucleotide analogues[J]. Ann NY Acad Sci, 1990, 616:398-407.
  • 2[2]Safrin S. Treatment of acyclovir-resistant herpes simplex virus infections in patients with AIDS[J]. J Acquir Immune Defic Syndr, 1992, 5(Suppl 1):S29-S32.
  • 3[3]Naesens L, Balzarini J, De Clercq E. Pharmacokinetics in mice of the anti-retrovirus agent 9-(2-phosphonylmethoxyethyl)adenine[J]. Drug Metab Dispos, 1992, 20(5):745-752.
  • 4[4]Shaw JP, Louie MS, Krishnamurthy VV, Arimilli MN, Jones RJ, Bidgood AM, et al. Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats[J]. Drug Metab Dispos, 1997, 25(3):362-366.
  • 5[5]Yves B, Bochet M, Thibault V, Calvez V, Fievet MH, Sullivan M. Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients[J]. J Hepatol, 2002, 36(Suppl 1):S138.
  • 6[6]Cundy KC, Fishback JA, Shaw JP, Lee ML, Soike KF, Visor GC, et al. Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys[J]. Pharm Res, 1994, 11(6):839-843.
  • 7[7]Cundy KC, Barditch-Crovo P, Walker RE, Collier AC, Ebeling D, Toole J, et al. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients[J]. Antimicrob Agents Chemother, 1995, 39(11):2401-2405.

共引文献3

同被引文献1

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部